Abstract
Mast cells play a central role in the pathophysiology of allergic diseases. Mast cell activation, proliferation and survival is dependent on KIT (CD117) signaling. THB001 is an inhibitor of wild type KIT being developed as a potential therapy for mast cell driven diseases. A first-in-human study was performed to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of THB001.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
